Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with ...

Chronic obstructive pulmonary disease, or COPD, is the 5th-leading cause of death in the United States and the cause of more ...

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...

Experts report that a chronic cough lasting at least 8 weeks disproportionately affects women, with prevalence increasing with age.

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough ...

Q4 2025 Management View Jennifer Good, CEO, reported that "2025 was a major inflection point for growth at Trevi, driven by our positive data readouts in both the CORAL trial in patients with ...

A Maryland man was sentenced after conspiring with a Virginia-based doctor who wrote fake prescriptions to distribute drugs ...

As GLP-1 use has expanded well beyond obesity and diabetes, clinicians are encountering a broader range of real-world symptoms — some anticipated, others less clearly defined. For primary care ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of ...

They’ve been hailed as miracle drugs, helping millions shed stubborn pounds and cutting the risk of heart attack and stroke by around 20 per cent. But as the use of GLP-1 weight-loss jabs has soared, ...

Specialists are more likely than primary care providers to view chronic cough as sensory neuropathy and prescribe neuromodulators for treatment. A clinician’s specialty, degree, and personal risk ...